SABCS 2022 | Low-dose tamoxifen for the treatment of high-risk breast cancer

Andrea De Censi, MD, PhD, National Hospital E.O. Ospedali Galliera – S.C. Oncologia Medica, Genoa, Italy, discusses low-dose tamoxifen for the treatment of choice for high-risk breast cancer, including ductal carcinoma in situ (DCIS). This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.